grennreversedReNeuroGen LLC_testtubes_ce

A virtual pharmaceutical company developing systems pharmacology therapies with a focus on neurological and pulmonary disease indications.

 
Image by Chromatograph

INNOVATION

ReNeuroGen is pursuing first-in-class systems chemico-pharmacology agents that impact multi-target disease states and set in motion a cascade of effects that hasten amelioration of symptoms.

 
Scientist in the Lab

TRIPEPTIDE MYELOPEROXIDASE INHIBITORS

KYC, our lead candidate, is a powerful agent that inhibits inflammation and processes associated with certain diseases that damage healthy cells. KYC binds myeloperoxidase (MPO), converts KYC to a free radical that inhibits the inflammatory cascade as well as MPO's production of toxic oxidants.

Experiment

DISEASES TREATED

ReNeuroGen is currently developing KYC (N-acetyl-lysyltyrosylcysteine amide) as a treatment for Sickle Cell Disease. We also believe KYC has potential for treating Multiple Sclerosis, Brain Injury and Bronchopulmonary Dysplasia.

ThreeAmigos.jpg

LEADERSHIP TEAM

Stephen Naylor, Ph.D. -- Co-Founder, CEO and Board Chairman. He was Founder, CEO and Chairman of Predictive Physiology & Medicine (PPM) Inc, one of the world’s first personalized medicine companies. He serves as an Advisory Board Member of CureHunter Inc, a computational biology drug discovery company, and as a business adviser to the not-for-profit Cures Within Reach. In the past, he has held professorial chairs in Biochemistry & Molecular Biology, Pharmacology, Clinical Pharmacology, and Biomedical Engineering at Mayo Clinic in Rochester, Minnesota. He holds a Ph.D. from the University of Cambridge (UK) and undertook an NIH-funded fellowship at MIT located in the ‘other’ Cambridge. He has raised over $100M for research and corporate efforts.

Kirkwood A. Pritchard, Jr., Ph.D. -- Co-Founder, CSO and Board Director. He is a tenured Research Professor in the Division of Pediatric Surgery, Department of Surgery, at the Medical College of Wisconsin (Milwaukee, Wisconsin). He has broad and diverse translational research interests in a number of disease indications including, stroke, multiple sclerosis, traumatic brain injury, sickle cell disease, and bronchopulmonary dysplasia in premature babies. He holds a Ph.D. from Ohio State University and undertook a postdoctoral fellowship at Albert Einstein College of Medicine. He has raised over $15M for research efforts.

Billy W. Day, Ph.D. -- COO. He has basic and applied research interests in medicinal, analytical, computational, and toxicological chemistry, and in biomarker discovery/quantitation. In the past, he was professor of Pharmaceutical Sciences, of Chemistry, and of Computational & Systems Biology at the University of Pittsburgh. He was also Chief Science Consultant at the disease modeling company Immunetrics, Inc. He received a Ph.D. in Medicinal Chemistry from the University of Oklahoma Health Sciences Center and was a postdoctoral fellow in Toxicology and Chemistry at MIT. He has raised over $25M for research and corporate efforts.

Business Morning

NEWS

 

KYC REDUCES BRONCHOPULMONARY DYSPLASIA

Spring 2021

INHIBITION OF MYELOPEROXIDASE INCREASES REVASCULARIZATION

Spring 2020

THE REALITY OF VIRTUAL PHARMACEUTICAL COMPANIES

Summer 2019

INTEGRATED PLATFORM DRUG DISCOVERY COMPANIES, PART II

Spring 2019

SYSTEMS PHARMACOLOGY

Winter 2018/19

EMERGING PARADIGM - INTEGRATED PLATFORM DRUG DISCOVERY COMPANIES

Fall 2018

MYELOPEROXIDASE: A NEW PLAYER IN AUTOIMMUNITY

Fall 2017

INHIBITION OF MYELOPEROXIDASE OXIDANT PRODUCTION BY KYC REDUCES BRAIN DAMAGE

Spring 2016

CONTACT US

Elm Grove, WI 53122, USA

1-412-972-0134

brain_newgreen_r_eNeuroGenLLC.jpg
 

1-412-972-0134

  • Facebook
  • Twitter

©2020 by ReNeuroGen LLC. Proudly created with Wix.com